Biofrontera (BFRI) Other Accumulated Expenses (2024 - 2025)
Biofrontera's (BFRI) quarterly Other Accumulated Expenses came in at $320000.0 in Q4 2025, down 47.8% year-on-year from $613000.0 in Q4 2024, and down 53.01% quarter-over-quarter from $681000.0 in Q3 2025.
Biofrontera (BFRI) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Biofrontera's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $320000.0 for Q4 2025.
- On a quarterly basis, Other Accumulated Expenses fell 47.8% year-over-year to $320000.0 in Q4 2025; TTM through Dec 2025 was $320000.0, a 47.8% decrease from a year earlier, with the FY2025 full-year figure at $320000.0, down 47.8% from the prior year.
- Other Accumulated Expenses retreated to $320000.0 in Q4 2025 per BFRI's latest filing, from $681000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $683000.0 in Q2 2025 and bottomed at $320000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Biofrontera | 12.70 Mn | 6.29 Mn | 14.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 320,000.00 |
| Sep 30, 2025 | 681,000.00 |
| Jun 30, 2025 | 683,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 613,000.00 |